Mitomycin C Intravesical Chemotherapy in Conjunction With Synergo® Radiofrequency-Induced Hyperthermia for Treatment of Carcinoma in Situ Non-Muscle Invasive Bladder Cancer Patients Unresponsive to Bacillus Calmette-Guérin, With or Without Papillary Tumors.

Bladder Cancer Clinical Trial

— RITE-USA  

Official title:

A Multicenter, Single-Arm Study Evaluating the Efficacy of Synergo® Radiofrequency-Induced Thermochemotherapy Effect (RITE) With Mitomycin C (Synergo® RITE + MMC) in CIS Non-Muscle Invasive Bladder Cancer (NMIBC) Bacillus Calmette-Guérin (BCG)-Unresponsive Patients With or Without Papillary NMIBC

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03335059
• Other study ID #: RITE-1
• Status: Terminated
• Phase: Phase 3
• Start date: April 4, 2019
• Est. completion date: February 26, 2020

Study information

• Verified date: April 2020
• Source: Medical Enterprises Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will determine whether Synergo® RITE + MMC treatment is efficacious as second-line therapy for CIS NMIBC BCG-unresponsive patients with or without papillary NMIBC, through examination of the complete response rate (CRR) and disease-free duration for complete responders. The study will also explore progression-free survival time, bladder preservation rate, and overall survival time.

The study will address an unmet need to identify a treatment effective in both ablating the disease and providing a prolonged disease-free period for patients. Ideally, the treatment will delay progression to invasive disease, thus preserving the bladder.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 5
• Est. completion date: February 26, 2020
• Est. primary completion date: February 26, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patients with current CIS of the bladder, with or without coexisting papillary Ta/T1 NMIBC tumor(s), who experienced an occurrence or recurrence of CIS within 12 months of completion of adequate BCG7 therapy. An adequate BCG regimen shall consist of at least 2 courses of BCG where the first course (induction) must have included at least 5 of 6 weekly treatments and the second course may have included a re-induction (at least 2 of 6 treatments) or maintenance, (at least 2 of 3 treatments) administered on a schedule similar to the SWOG 8507 study regimen.

2. All clinical, intra-operative and pathological items for the AUA risk stratification must be documented. This includes bladder mapping, according to the instructions specified in the protocol. With regard to BCG and/or other NMIBC treatments documentation must include:

1. Date of initial treatment,

2. Date of last treatment,

3. The number of courses administered and the number of treatments administered in each course.

3. Patients with concomitant papillary tumor(s) must have undergone a repeat TUR 2-4 weeks prior to the first study treatment:

1. if the previous TUR was incomplete,

2. if there was no muscle in the specimen after the initial TUR (except in TaLG tumors),

3. in all T1,

4. in all HG tumors = 3cm.

4. CT-IVU or MRI-IVU or IVU/retrograde confirmation of absence of tumor(s) in the upper tract, kidney and ureters performed within 6 months before the study treatment initiation, in selected cases, as recommended in latest AUA guidelines published prior to screening. If IVU/retrograde protocol is not available or contrast allergy/poor renal function preclude such imaging, then non-contrast CT or MRI of the abdomen/pelvis within the same timeframe will suffice.

5. Visual inspection to exclude urothelial carcinoma (UC) in the urethra during cystoscopy.

6. Biopsy of the prostatic urethra, prior to enrollment, to exclude UC of the prostatic urethra, in male patients with:

1. tumor of trigone,

2. tumor of bladder neck, or

3. abnormal prostatic urethra

4. prior history of prostatic urethral involvement.

7. All patients must have urine cytology collected from either voided urine or bladder wash within the screening period prior to enrollment. Patients with positive cytology must also have selective cytology from the upper tract and prostatic urethral biopsies collected within the same period. Patients with a localizing positive upper tract cytology are excluded from the study until definitive treatment renders them free of disease visually and/or radiographically and cytologically (nephroureterectomy, distal ureterectomy or upper tract therapy).

8. Age = 18 yrs.

9. No evidence of urothelial cancer in either kidneys or ureters.

10. Pre-treatment hematology and biochemistry values within the limits:

1. Hemoglobin = 10 g/dl (g/100 ml)

2. Platelets = 150 x 10^9/L (x 10^3/mm^3)

3. WBC = 3.0 x 10^9/L (x 10^3/mm^3)

4. ANC = 1.5 x 10^9/L (x 10^3/mm^3)

5. Serum creatinine < 2 mg/dl

6. SGOT < 1.5 x ULN

7. SGPT < 1.5 x ULN

8. Alkaline phosphatase < 1.5 x ULN

11. Negative pregnancy test for women of childbearing potential.

12. A life expectancy at least of the duration of the study.

13. Signed informed consent.

Exclusion Criteria:

1. Non-UC tumor of the urinary tract.

2. Upper tract and/or intramural tumors (e.g., in ostium).

3. Positive selective cytology from the upper tract.

4. History of stage > T1 UC.

5. Papillary tumors > T1 in repeat TUR.

6. Known or suspected reduced bladder capacity. Patients will have an ultrasonic estimation of maximum bladder capacity or void spontaneously the maximum they can retain in their bladder, and this will be used to determine urine volume. A minimum volume of 250 ml is required.

7. Patients with severe bladder outlet obstruction not adequately controlled with medication (AUA symptom score = 20).

8. Bleeding disorder.

9. Gross hematuria within the past 2 weeks before treatment start.

10. Lactating women.

11. Women of childbearing potential unwilling or unable to use adequate contraception if sexually active.

12. More than low-dose methotrexate (>17.5 mg once a week).

13. Other malignancy within the past 5 years, except: non melanomatous skin cancer cured by excision, surgically treated carcinoma in situ of the cervix or ductal CIS (DCIS)/lobular CIS (LCIS) of the breast or stable prostate cancer (under active surveillance or hormone control) with a life expectancy of more than 5 years.

14. Any known allergy (e.g., to MMC) or adverse event that would prevent a prospective study participant from receiving the study treatment.

15. Known untreated urethral strictural disease or bladder neck contracture or any other condition that may prevent catheterization with a 21F catheter. Patients may undergo dilation or urethral incision before entering the study.

16. Bladder diverticulum with diameter > 1cm, as determined by CT or cystography

17. UTI at any time within 3 weeks before study treatment initiation.

18. Significant urinary incontinence (spontaneous, requiring use of > 1 pad/day (PPD)).

19. History of pelvic irradiation.

20. Patients with electronic devices implanted in abdominal cavity.

21. Participation in another study, unless discussed with and approved by the Sponsor or Sponsor's authorized representative.

Related Conditions & MeSH terms

• BCG-Unresponsive Bladder Cancer
• Bladder Cancer
• Bladder Neoplasm
• Bladder Tumors
• Cancer of Bladder
• Cancer of the Bladder
• Carcinoma
• Carcinoma in Situ
• Carcinoma in Situ of Bladder
• Malignant Tumor of Urinary Bladder
• Neoplasms
• Neoplasms, Bladder
• Papillary Carcinoma of Bladder (Diagnosis)
• Urinary Bladder Cancer
• Urinary Bladder Neoplasms

Intervention

Combination Product:
• Synergo® RITE + MMC
Subjects will receive a series of induction followed by a series of maintenance bladder instillations of Synergo® RITE + MMC

Locations

Country	Name	City	State
United States	Chesapeake Urology Research Associates	Hanover	Maryland
United States	Icahn School of Medicine at Mount Sinai	New York	New York
United States	Memorial Sloan Kettering Cancer Center	New York	New York
United States	University of Pennsylvania	Philadelphia	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
Medical Enterprises Ltd.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	complete response rate (CRR)	no CIS; no papillary HG tumor; no papillary T1 tumor; no extra-vesical UC tumor; no progression; a patient will be considered a complete responder only if all the criteria above are met.; Patients experiencing a new occurrence of a benign tumor or low-grade Ta will be allowed to continue in the study (tumor will be resected); such an occurrence will not constitute an event in the primary analysis.; Patients with tumors of the ostium and/or upper tract and/or prostatic urethra will be considered to have achieved a complete response in the primary analysis but will be removed from the study.	3 months after the initiation of study therapy
Secondary	disease-free duration of complete response (DCR)	time of recurrence for complete response patients from the 3-month visit until the time of recurrence or until the last follow-up, whichever occurs sooner.	through study completion, up to 33 months